We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBiocure Technology Inc

Biocure Technology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-12T17:10:00.571967Z
Market Cap
1.41M
P/E
0.50

Momentum Score

…

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.04
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biocure Technology Inc is a Canada-listed life-sciences company; public disclosures are limited, but it appears positioned in biotechnology and medical technologies. Long-term growth may depend on product development progress, regulatory approvals, strategic partnerships and access to capital, which could support commercialization prospects and potential upside for investors.

Key risks include limited public information, development and clinical/regulatory setbacks, significant capital requirements and low stock liquidity that could materially affect execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
-0.00M
Revenue Per Share
-
Gross Profit TTM
-0.00M
Debt / Equity
-
ROE
45.21%
Net Debt
0.02M
ROCE
-5.77%
Diluted EPS TTM
0.03

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.10M -0.26M -1.49M -0.40M -1.15M
Minority interest - 0.00M 0.03M 0.06M 0.02M
Net income -0.10M -0.26M -1.81M -1.45M -1.13M
Selling general administrative 0.06M 0.32M 0.33M 0.67M 2.34M
Reconciled depreciation - - - 0.02M 0.08M
Ebit - - - - -1.73M
Ebitda - - - -0.40M -0.58M
Operating income -0.09M -0.34M -1.08M -0.69M -3.90M
Interest expense 0.01M 0.01M 0.01M 0.00M 0.50M
Interest income - - - - 0.09M
Net interest income -0.01M -0.01M -0.01M -0.00M -0.41M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.09M 0.34M 1.08M 0.69M 3.90M
Total other income expense net -0.00M 0.09M -0.41M 0.29M 3.16M
Discontinued operations - - - - 0.72M
Net income from continuing ops -0.10M -0.26M -1.49M -0.40M -1.15M
Net income applicable to common shares - - - - -1.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.01M 1.99M 1.98M 2.08M 4.15M
Intangible assets - - - 0.00M 0.00M
Other current assets - - - 0.06M 1.89M
Total liab 0.44M 0.65M 0.37M 4.06M 5.01M
Total stockholder equity 1.58M 1.34M 1.60M -1.98M -0.53M
Other current liab - - - 3.62M -
Common stock - - - 18.45M 18.38M
Capital stock 18.01M 17.68M 17.68M 18.45M 18.38M
Retained earnings -23.94M -23.83M -23.57M -20.01M -26.08M
Other assets - - - 0.00M 0.04M
Cash 0.04M 0.02M 0.00M 0.04M 0.16M
Total current liabilities 0.44M 0.60M 0.33M 4.41M 3.75M
Net debt 0.02M 0.03M 0.04M 0.04M 3.63M
Short term debt - - - 0.08M 0.00M
Short long term debt 0.06M - - 0.08M 2.53M
Other stockholder equity - - - -0.42M 7.17M
Property plant equipment - - - 0.00M 0.01M
Total current assets 0.05M 0.03M 0.01M 0.12M 2.13M
Long term investments 1.97M 1.97M 1.97M 1.97M 1.97M
Net tangible assets - - - - -0.53M
Net receivables - - - 0.02M 0.01M
Long term debt - 0.05M 0.04M 0.00M 1.25M
Inventory - - - 0.00M 0.00M
Accounts payable 0.35M 0.60M 0.33M 0.71M 0.94M
Non current assets total 1.97M 1.97M 1.97M 1.97M 2.02M
Capital lease obligations - - - 0.00M 0.00M
Long term debt total - - - 0.00M 1.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.04M 0.07M -0.00M
Change to liabilities - - - - 0.30M
Total cashflows from investing activities - - - 0.07M 0.03M
Net borrowings - 0.00M -0.05M 0.00M 0.07M
Total cash from financing activities 0.10M 0.00M -0.05M 0.63M 1.17M
Change to operating activities - - - - -0.05M
Net income -0.10M -0.26M -1.81M -1.45M -1.13M
Change in cash 0.02M 0.01M -0.03M -0.12M 0.11M
Begin period cash flow 0.02M 0.00M 0.04M 0.16M 0.05M
End period cash flow 0.04M 0.02M 0.00M 0.04M 0.16M
Total cash from operating activities -0.08M 0.01M -0.22M -0.83M -1.08M
Issuance of capital stock 0.10M - - 0.03M 1.10M
Depreciation - - - 0.02M 0.08M
Other cashflows from investing activities - - - 0.07M 0.45M
Change to inventory - - - 0.00M 0.00M
Change to account receivables - - - - -0.01M
Sale purchase of stock - - - 0.00M 0.99M
Other cashflows from financing activities - - - 0.63M 0.24M
Change to netincome - - - - -0.20M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.02M 0.27M 0.25M 0.49M 1.72M
Stock based compensation - - - 0.00M 1.16M
Other non cash items 0.01M 0.01M 0.01M 0.01M 0.27M
Free cash flow -0.08M 0.01M -0.22M -0.82M -1.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DRUG
Bright Minds Biosciences Inc		 0.06
0.19%		 32.18 - - - 13.50 -0.10
METX
ME Therapeutics Holdings Inc.		 -
-%		 1.05 - - - 72.00 -
TELI
Telescope Innovations Corp.		 -
-%		 0.34 - - 4.32 6.45 -1.62
DTC
Defence Therapeutics Inc		 -
-%		 0.31 - - - 89.80 -9.99

Profile*

Biocure Technology Inc

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9

604-609-7146

https://www.biocuretech.com

Name Title Year Born
Dr. Björn Cochlovius Ph.D. President NA
Mr. Konstantin Lichtenwald B.B.A., CPA, CGA CFO, Corporate Secretary & Director 1984
Mr. Yee Sing Cheng CEO & Director 1981
Mr. Marco Nonni Consultant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…